前沿速览054期| CAR-T治B淋 前沿览新知
01
肠道菌群及丁酸盐对CAR-T细胞疗法治疗非霍奇金淋巴瘤的增效潜力
The Potential of the Gut Microbiota and Butyrate to Enhance CAR-T Cell Therapy in Non-Hodgkin Lymphoma
第一作者：Garcia-Vicente R
Clin Cancer Res (IF=10.2). 2025 Nov 13.
全文网址：https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-25-1676/767246/The-Potential-of-the-Gut-Microbiota-and-Butyrate
02
Axicabtagene Ciloleucel联合Atezolizumab治疗难治性弥漫性大B细胞淋巴瘤：ZUMA-6 I/II期研究
Axicabtagene Ciloleucel in Combination With Atezolizumab in Patients With Refractory Diffuse Large B-cell Lymphoma: The Phase 1/2 ZUMA-6 Trial
第一作者：Jacobson CA
Clin Cancer Res (IF=10.2). 2025 Nov 13.
全文网址：https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-25-0602/767245/Axicabtagene-Ciloleucel-in-Combination-With
03
CD19 CAR-T细胞疗法治疗血管内大B细胞淋巴瘤
CD19 directed CAR T therapy for intravascular large B-cell lymphoma
第一作者：Patel J
Haematologica (IF=7.9). 2025 Nov 6.
全文网址：https://haematologica.org/article/view/12984
04
CD19 CAR-T治疗后序贯PD-1抑制剂巩固治疗复发/难治性非霍奇金淋巴瘤：一项倾向评分匹配队列研究
Sequential PD-1 inhibitors as consolidative therapy post-CD19 CART in relapsed/refractory NHL: a propensity score matching cohort study
第一作者：Xue B
J Transl Med (IF=7.5). 2025 Nov 7;23(1):1247.
全文网址：https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-025-07281-w
05
种族与临床因素对2304例复发/难治性B细胞淋巴瘤患者接受CD19 CAR-T细胞治疗疗效的影响
Racial and Clinical Determinants of Response in 2,304 r/r BCL Treated with Anti-CD19 CAR T-Cells in Clinical Trials
第一作者：Kho SJ
Blood Adv (IF=7.1). 2025 Nov 7:bloodadvances.2025016361.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2025016361/548107/Racial-and-Clinical-Determinants-of-Response-in-2
06
单一评分系统是否适用于所有患者？CAR-HEMATOTOX、ALL-HEMATOTOX及eIPM预测CAR-T细胞治疗血液恶性肿瘤后免疫效应细胞相关血液毒性的比较研究
Can one scoring system fit all? Comparative validation of CAR-HEMATOTOX, ALL-HEMATOTOX, and eIPM for predicting immune effector cell-associated hematotoxicity following CAR-T therapy in hematologic malignancies
第一作者：Zhang A
Chin J Cancer Res (IF=6.3). 2025 Oct 30;37(5):705-717.
全文网址：http://article.cjcrcn.org/en/article/doi/10.21147/j.issn.1000-9604.2025.05.04?viewType=HTML
07
桥接放疗在CAR-T治疗非霍奇金淋巴瘤中的应用：系统评价与荟萃分析
Bridging radiotherapy for chimeric antigen receptor T cells therapy in non-Hodgkin lymphoma: Systematic review and meta-analysis
第一作者：Lam EK
Radiother Oncol (IF=5.3). 2025 Nov 1;214:111258.
全文网址：https://www.thegreenjournal.com/article/S0167-8140(25)05262-4/abstract
08
中枢神经系统淋巴瘤CAR-T细胞治疗后采用PD-1与BTK抑制剂维持治疗获得持续缓解
Sustained remission with PD-1 and BTK inhibitors maintenance after chimeric antigen receptor T-cell therapy in CNS lymphoma
第一作者：Yu L
Cancer Immunol Immunother (IF=5.1). 2025 Nov 12;74(12):372.
全文网址：https://link.springer.com/article/10.1007/s00262-025-04236-4
09
倾向评分匹配分析支持CAR-T细胞疗法联合自体移植改善复发/难治性弥漫性大B细胞淋巴瘤患者生存：一项中国真实世界研究的证据
Propensity Score-Matched analysis supports the survival benefits of combination chimeric antigen receptor T-cell therapy with autologous transplantation in relapsed or refractory diffuse large B-cell lymphoma: Insights from a real-world study in China
第一作者：Sheng K
Transplant Cell Ther (IF=4.4). 2025 Nov 4:S2666-6367(25)01547-7.
全文网址：https://www.sciencedirect.com/science/article/abs/pii/S2666636725015477?via%3Dihub
10
CD19 CAR-T细胞治疗复发/难治性弥漫性大B细胞淋巴瘤的清淋方案比较分析
Comparative Analysis of Lymphodepletion Regimens in CART-19 Treatment for Relapsed/Refractory Diffuse Large B Cell Lymphoma
第一作者：Christodoulou I
Transplant Cell Ther (IF=4.4). 2025 Nov 1:S2666-6367(25)01544-1.
全文网址：https://www.sciencedirect.com/science/article/abs/pii/S2666636725015441?via%3Dihub
免责声明：本资料为专业医学资料，旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参考；任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗，不能替代专业医学意见。
审批编号：NP-NHL-2025.11-17 valid until 2027.11
供稿与审核：临床开发与医学部